Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Exercício Intervalado de Alta Intensidade em Jovens Adultos Sobreviventes de Tumores Cerebrais Pediátricos: Um Estudo Piloto de Viabilidade (HYPE)

3 de novembro de 2026 atualizado por: Christina Dieli-Conwright, PhD, Dana-Farber Cancer Institute

Exercício Intervalado de Alta Intensidade em Jovens Adultos Sobreviventes de Tumores Cerebrais Pediátricos: Um Estudo Piloto de Viabilidade (HYPE)

The purpose of this study is to determine whether a 16-week virtual, home-based, high-intensity interval training (HIIT) exercise program will improve physical, cognitive, and emotional health among young adult survivors of pediatric brain tumors.

The names of the study interventions involved in this study are/is:

  • High-Intensity Interval Training (HIIT)

Visão geral do estudo

Descrição detalhada

This is a Pilot/Feasibility, randomized control, research study that will compare an exercise group to a control group on physical, social, and overall quality of life needs of pediatric brain tumor survivors who are now young adults.

Participants will be randomized (selected at random) for two groups: HIIT program group will complete a 16-week intervention period followed by a 16-week period with no intervention and the waitlisted control group will complete a 16-week period and will perform their usual, daily activities followed by an optional 16-week period in which they can complete the HIIT program.

Research procedures include screening for eligibility, study treatment including in-clinic evaluations of fitness and strength, blood collection, at-home zoom exercise sessions, self-administered activity logs, and survey questionnaires.

Participation in this research study is expected to last about 8 months.

It is expected that about 30 people will take part in this research study.

The Stahl Family Charitable Foundation, Pedal 4 Pediatrics, and the Childhood Brain Tumor Foundation are supporting this research study by providing funding for the study.

Tipo de estudo

Intervencional

Inscrição (Estimado)

30

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02215
        • Recrutamento
        • Dana Farber Cancer Institute
        • Contato:
        • Investigador principal:
          • Christina M Dieli-Conwright, PhD

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 45 anos (Adulto)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Written informed consent prior to any study-related procedures.
  • At time of study are a young adult, aged 18-45 years.
  • Histologically diagnosed brain tumor during childhood, or currently diagnosed with an IDH-mutant glioma (diagnosed > 18 years).
  • Are at least 2 years post tumor-directed therapy for pediatric brain tumor survivors, or at least 1 year since their most recent surgery, radiation or chemotherapy treatment for IDH-mutant glioma patients (or are deemed able to participate in the study based on the assessment of their treating physician). IDH-mutant glioma patients can participate while on maintenance therapy with an IDH inhibitor.
  • The effects of exercise on the developing fetus are unknown. For this reason, people of child-bearing potential must verify pregnancy status by providing first day of their last menstrual cycle and agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry. Should a person become pregnant or suspect that they are pregnant while participating on the trial, they should inform their treating physician immediately.
  • Medically cleared to participate in exercise by their referring physician or a certified clinical exercise physiologist.
  • If participants have a diagnosis of tumor-related epilepsy, they must have good seizure control, with no generalized seizures in the 6 months preceding enrollment.
  • Are without any other medical conditions that could exacerbate with exercise, such as bone disease (excluding bone metastases) at imminent risk of fracture or uncontrolled cardiopulmonary or metabolic diseases.
  • Speak English and/or Spanish.
  • Currently participate in less than or equal to 60 minutes of moderate or vigorous structured exercise/week.
  • Does not smoke cigarettes or e-cigarettes (no smoking during the previous 12 months). Those who infrequently smoke in social settings will be included. Those who vape will also be included.
  • Willing to travel to DFCI for necessary data collection.
  • Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  • Diagnosis of primary spinal cord tumor.
  • Pre-existing medical conditions such as uncontrolled tumor-related epilepsy, cardiopulmonary disease, or metabolic diseases that could exacerbate with exercise.
  • Patients with evidence of progressive CNS or systemic cancer in the last 3 months.
  • People who are pregnant, or plan to become pregnant during study duration will be excluded due to the unknown nature of exercise on developing fetuses.
  • Actively on a weight loss diet.
  • Participate in more than 60 minutes of moderate or vigorous structured exercise/week.
  • Currently and regularly smokes.
  • Unable to travel to DFCI for necessary data collection.
  • May not be able to comply with the safety monitoring requirements of the study in the opinion of the investigator.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Cuidados de suporte
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: HIIT Exercise Program Group

Participants will be randomly assigned to the HIIT exercise group and receive:

  • 3x weekly for 16 week home-based virtually supervised High-Intensity Interval Training.
  • 16-week self-directed exercise follow up period.
  • 3 On-site visits at Week 1, 18 and 34 for assement testing and completion of questionnaires

Exercise program with stationary bike via the Zoom platform.

Outros nomes:
  • Treinamento Intervalado de Alta Intensidade
Comparador Ativo: Control Group

Participants will be randomly assigned to the HIIT waitlist control group and receive:

  • Daily usual activities
  • 2 On-site visits at Week 1, and 18 for assement testing and completion of questionnaires
  • Option to complete 16 week, 3x weekly HIIT exercise program after initial 16 week period.

Usual Activities

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Attendance of Exercise Sessions
Prazo: From first exercise session to final exercise session, up to 16 weeks

Defined as participant attendance of >= 70% of the 48 HIIT exercise sessions.

From first exercise session to final exercise session, up to 16 weeks
Completion in Minutes of Exercise Sessions
Prazo: From first exercise session to final exercise session, up to 16 weeks

Defined as participant completion of >= 70% of the 90 minutes of exercise per week

From first exercise session to final exercise session, up to 16 weeks
HIIT Compliance
Prazo: From first exercise session to final exercise session, up to 16 weeks

Defined as obtaining +-5W of target power output for >= 40 seconds of high intensity minute

From first exercise session to final exercise session, up to 16 weeks
Barriers to Exercise Adherence
Prazo: From first exercise session to final exercise session, up to 16 weeks

Assessed through the 17-item Barriers to Recruitment Participation Questionnaire (BRPQ), 1-5 scale with 1 denoted as strongly agree and 5 as strongly disagree.

From first exercise session to final exercise session, up to 16 weeks
Participant Burden
Prazo: From first exercise session to final exercise session, up to 16 weeks

Assessed through the Perceived Research Burden Assessment (PRBA), 1-5 scale with 1 denoted as strongly disagree and 5 as strongly agree.

From first exercise session to final exercise session, up to 16 weeks

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Cognition
Prazo: : From baseline to post-intervention, up to 43 weeks

An assortment of tests will be executed through the NIH toolbox to measure overall cognition.

: From baseline to post-intervention, up to 43 weeks
Cardiorespiratory Fitness
Prazo: From baseline to post-intervention, up to 43 weeks

Assessed through the use of a VO2 max (or submaximal if equipment is unavailable) cycle exercise stress test (Parvo Medics TrueOne 2400; Sandy, UT, USA).

From baseline to post-intervention, up to 43 weeks
Muscular Strength
Prazo: From baseline to post-intervention, up to 43 weeks

10-repetition maximum will be used to assess muscular strength.

From baseline to post-intervention, up to 43 weeks
Body Composition
Prazo: From baseline to post-intervention, up to 43 weeks

Bioelectrical Impedance Analysis (BIA), and blood pressure as measured twice on both arms with a seated position with a minimum of 1-minute interval and the higher pressure will be recorded when there are differences.

BIA: Assessed via bioelectrical impedance using a validated device (Tanita 780, Arlington Heights, IL). Participants will be asked to remove their shoes and socks after which height will be taken using a stadiometer they will then proceed to move to the BIA and stand still on the device while holding the handles with their hands at their sides. The device will estimate body fat using an algorithm based on their age, sex, height, and body weight.

From baseline to post-intervention, up to 43 weeks
Fatigue
Prazo: From baseline to post-intervention, up to 43 weeks

BFI: A questionnaire of scale ratings 0 - 10 that focuses on cancer-related fatigue and tiredness.

From baseline to post-intervention, up to 43 weeks
Psychosocial Health
Prazo: From baseline to post-intervention, up to 43 weeks

Assessed through the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire, which is comprised of 27 items with scale ratings validated to measure physical, emotional, social, and functional well-being of cancer patients and survivors

From baseline to post-intervention, up to 43 weeks
Quality of Sleep
Prazo: From baseline to post-intervention, up to 43 weeks

Assessed through the Pittsburg Sleep Quality Index (PSQI), which is used to measure 7 components of the quality and patterns of sleep in participants.

From baseline to post-intervention, up to 43 weeks
Dietary Assessment, ASA-24
Prazo: Up to 3 days

Participants will be provided with a login to enter dietary data measured by an automated, online self-administered 24-hour assessment tool.

Up to 3 days
ActiGraph - Physical Activity Monitoring
Prazo: From baseline to post-intervention, up to 27 weeks

Participants will be provided with an accelerometer (ActiGraph, Pensacola, FL) to wear for seven days at baseline and post-intervention testing visits and will be instructed to wear the water-resistant accelerometer at all times except for when swimming or bathing. The device will record activity data and will be electronically transferred to a computer via USB cable at time of completion.

From baseline to post-intervention, up to 27 weeks
Exercise Tolerance
Prazo: From baseline to week 16, up to 32 weeks

Will be recorded using the Exercise-Induced Feeling Inventory (EIF). Based on a 0-4 scale, it assesses the participant's feeling state change(s) post-exercise and is also used for the assessment of self-motivation to adhere to an exercise regimen. Participants will be asked to complete the inventory before and after each exercise session.

From baseline to week 16, up to 32 weeks
Pain Index
Prazo: From baseline to post-intervention, up to 43 weeks

BPI: A 9 item questionnaire to evaluate the severity of pain and the impact of pain on the participant's daily functioning.

From baseline to post-intervention, up to 43 weeks
Hip and Waist Circumference
Prazo: From baseline to post-intervention, up to 43 weeks

Hip and waist circumference will be assessed and recorded in cm.

From baseline to post-intervention, up to 43 weeks

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Christina Dieli-Conwright, PhD, MPH, Dana-Farber Cancer Institute

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

4 de dezembro de 2023

Conclusão Primária (Estimado)

24 de setembro de 2027

Conclusão do estudo (Estimado)

24 de setembro de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

2 de fevereiro de 2023

Enviado pela primeira vez que atendeu aos critérios de CQ

13 de fevereiro de 2023

Primeira postagem (Real)

23 de fevereiro de 2023

Atualizações de registro de estudo

Última Atualização Postada (Real)

6 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

3 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Prazo de Compartilhamento de IPD

Data can be shared no earlier than 1 year following the date of publication

Critérios de acesso de compartilhamento IPD

Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO
  • SEIVA

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever